Skip to content
★ Sign in to follow
Eyebright Medical Technology (Beijing) Co., Ltd. logo

Eyebright Medical Technology (Beijing) Co., Ltd. Stock: price and insider trades · China

爱博医疗

CN·Mcap CN¥8BHealth Care

No insider purchase over the last 90 days. The latest, by 周裕茜, was filed 26 Jun 2025.

Eyebright Medical Technology (Beijing) Co., Ltd.: what insiders have been doing

This page follows insider dealings at Eyebright Medical Technology (Beijing) Co., Ltd. as filed with SSE / SZSE (CSRC), a company from the Health Care sector. The past year has been quiet: not a single insider filing for Eyebright Medical Technology (Beijing) Co., Ltd. The previous disclosure was published on 26 June 2025.

The full history, which starts in 2024, counts 5 purchases against no sales.

In the same sector, recent insider purchases at Dynavox Group AB and Vetoquinol SA also feature in our signals. Every figure here comes from the filings published by SSE / SZSE (CSRC) and describes the past, not future prices; it is not investment advice.

Insider Decl.
5
Thresholds
n/a
Buy Volume
€209,924
5 ops. · all time
Sell Volume
n/a
n/a

Who traded when

BuySale
周裕茜1 buy

Since the insiders bought

  • Filed 26 Jun 2025 · 500 days ago · €25k
    +5.9%
    Entry CN¥69.01 · Close at T+90 CN¥73.10
  • Filed 27 Aug 2024 · 803 days ago · €28k
    +9.7%
    Entry CN¥73.06 · Close at T+365 CN¥80.18
  • Filed 26 Aug 2024 · 804 days ago · €74k
    +3.5%
    Entry CN¥73.50 · Close at T+365 CN¥76.05

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 10,178 of 26,912 companies
57.6
score / 100
Value
45
Quality
70
FCF yld3.1%
Earn yld3.3%
EV/EBITDA17.9x
ROE7.0%
Gross mgn63%
Net mgn18%
Debt/EBITDA1.2x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2025

FY ended December 2025 · cache

CN¥41.40
Analyst consensus
4 analysts
·
CN¥40.00Target CN¥52.00(+26%)CN¥66.00
Income statement
RevenueCN¥1.5B
Gross profitCN¥941.4M63% margin
EBITDACN¥481M32% margin
Net incomeCN¥268.2M14.6% margin
Valuation
PER (trailing)32.6x
PER (forward)19.0x
P/Book2.8x
Beta0.22
Balance sheet & cash
Market capCN¥8B
Total debtCN¥580.3M
Free Cash FlowCN¥246M
Debt / Equity39%
Profitability & ownership
ROE7.0%
ROA4.9%
% insiders33.3%
% institutions10.1%
Last declaration on 26 June 2025
Declarations5 total
  • ▲
    高级管理人员Executives
    211,869 CNY19SSE
    9,450 shares100.0% of flowA股XSHGSSE:173000009149770460
    Canonical exit: 24 Sept 2025 (T+90)
  • ▲
    董事,高级管理人员,核心技术人员Executives
    221,343 CNY25SSE
    3,053 shares60.0% of flowA股XSHGSSE:173000008014222430
    Canonical exit: 25 Nov 2024 (T+90)
  • ▲
    董事,高级管理人员,核心技术人员Executives
    590,990 CNY24SSE
    8,008 shares53.8% of flowA股XSHGSSE:173000008014222100
    Canonical exit: 24 Nov 2024 (T+90)
  • ▲
    董事,高级管理人员,核心技术人员Executives
    147,500 CNY23SSE
    2,000 shares40.0% of flowA股XSHGSSE:173000008014222400
    Canonical exit: 24 Nov 2024 (T+90)
  • ▲
    董事,高级管理人员,核心技术人员Executives
    497,488 CNY12SSE
    6,800 shares46.2% of flowA股XSHGSSE:173000007783241540
    Canonical exit: 23 Sept 2024 (T+90)

5 of 5 declarations

About Eyebright Medical Technology (Beijing) Co., Ltd.

爱博医疗 is a company specializing in the healthcare and pharmaceutical sector, listed on the XSHG market. It focuses on the development and commercialization of innovative medical products.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations